<DOC>
	<DOCNO>NCT00710684</DOCNO>
	<brief_summary>The study design investigate safety efficacy SB-742457 add stable donepezil treatment subject mild-to-moderate Alzheimer 's disease .</brief_summary>
	<brief_title>A Study SB-742457 , Added Donepezil Treatment Mild-to-moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Subjects caregiver must provide informed consent prior study entry . Subjects must clinical diagnosis probable mildtomoderate Alzheimer 's disease evidence disorder think cause , contribute severity subject 's dementia document history least 6 month ongoing donepezil therapy stable dose least last 2 month . Subjects must regular caregiver willing attend visit , oversee subject 's compliance study report subject 's status . Female subject childbearing potential must agree abstinence approve form birth control . Subjects must adequate blood pressure laboratory value . Subjects diagnosis possible , probable definite vascular dementia may participate . Subjects know hypersensitivity sunlight history seizure , previous exposure SB742457 , take agent theoretical risk interaction SB742457 , take medication Alzheimer 's disease centrally act agent might impact study outcome may participate .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Alzheimer 's disease cognition SB-742457</keyword>
</DOC>